Evidence map›Paper›PMID 20820776›Full record

ArticleCancer immunology, immunotherapy : CII2010

Alternative Ii-independent antigen-processing pathway in leukemic blasts involves TAP-dependent peptide loading of HLA class II complexes.

Marvin M van Luijn, Martine E D Chamuleau, Maaike E Ressing, Emmanuel J Wiertz, Suzanne Ostrand-Rosenberg, Yuri Souwer, Adri Zevenbergen, Gert J Ossenkoppele, Arjan A van de Loosdrecht, S Marieke van Ham

Open access · hybridAbstract read
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 2 countries.

Marvin M van LuijnDepartment of Hematology, Cancer Center Amsterdam, VU Institute for Cancer and Immunology, VU University Medical Center, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands. m.luijn@vumc.nl
Martine E D Chamuleau
Maaike E Ressing
Emmanuel J Wiertz
Suzanne Ostrand-Rosenberg
Yuri Souwer
Adri Zevenbergen
Gert J Ossenkoppele
Arjan A van de Loosdrecht
S Marieke van Ham
Cancer Center AmsterdamSanquin · NLAmsterdam UMC Location VUmc · NLUniversity Medical Center Utrecht · NLUniversity of Amsterdam · NLUniversity of Maryland, College Park · USUtrecht University · NL

Funding

Cell-based tumor vaccines targeting CD4+ T lymphocytesR01CA084232 · NCI · UNIVERSITY OF MARYLAND BALTIMORE COUNTY · PI OSTRAND-ROSENBERG, SUZANNE · 2000 to 2011
$2.6M
NCI NIH HHS R01 CA084232
6 · The paper itself

Abstract

During HLA class II synthesis in antigen-presenting cells, the invariant chain (Ii) not only stabilizes HLA class II complexes in the endoplasmic reticulum, but also mediates their transport to specialized lysosomal antigen-loading compartments termed MIICs. This study explores an alternative HLA class II presentation pathway in leukemic blasts that involves proteasome and transporter associated with antigen processing (TAP)-dependent peptide loading. Although HLA-DR did associate with Ii, Ii silencing in the human class II-associated invariant chain peptide (CLIP)-negative KG-1 myeloid leukemic cell line did not affect total and plasma membrane expression levels of HLA-DR, as determined by western blotting and flow cytometry. Since HLA-DR expression does require peptide binding, we examined the role of endogenous antigen-processing machinery in HLA-DR presentation by CLIP(-) leukemic blasts. The suppression of proteasome and TAP function using various inhibitors resulted in decreased HLA-DR levels in both CLIP(-) KG-1 and ME-1 blasts. Simultaneous inhibition of TAP and Ii completely down-modulated the expression of HLA-DR, demonstrating that together these molecules form the key mediators of HLA class II antigen presentation in leukemic blasts. By the use of a proteasome- and TAP-dependent pathway for HLA class II antigen presentation, CLIP(-) leukemic blasts might be able to present a broad range of endogenous leukemia-associated peptides via HLA class II to activate leukemia-specific CD4(+) T cells.

Indexed as

Antigen PresentationAntigens, Differentiation, B-LymphocyteATP-Binding Cassette TransportersBlast CrisisCell Line, TumorHistocompatibility Antigens Class IIHLA-DR AntigensHumansLeukemia, MyeloidProteasome Endopeptidase ComplexAntigens, Differentiation, B-LymphocyteATP-Binding Cassette TransportersHistocompatibility Antigens Class IIHLA-DR Antigensinvariant chainProteasome Endopeptidase Complextransporter associated with antigen processing (TAP)

Identifiers

PMID20820776
PMCPMC2945475
OpenAlexW2133784203

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.